Cargando…

Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation

PURPOSE: Despite newer type 2 diabetes (T2D) medications, patients do not always achieve metabolic targets, remaining at risk for cardiorenal complications. Therapeutic decisions are generally made by the healthcare team without considering patients’ preferences. We aimed to evaluate patients’ T2D t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa Gil, José Esteban, Garnica Cuéllar, Juan Carlos, Perez Terns, Paula, Ferreira-Hermosillo, Aldo, Cetina Canto, José Antonio, Garduño Perez, Ángel Alfonso, Mendoza Martínez, Pedro, Rista, Lucas, Sosa-Caballero, Alejandro, Vázquez-Mendez, Estefanía, Tejado Gallegos, Luis Fernando, Chen, Hungta, Elizalde, Agustina, Tomatis, Virginia B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112794/ https://www.ncbi.nlm.nih.gov/pubmed/35592774 http://dx.doi.org/10.2147/PPA.S355638

Ejemplares similares

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting
por: Chadha, Manoj, et al.
Publicado: (2022)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

DNA targeting by the type I-G and type I-A CRISPR–Cas systems of Pyrococcus furiosus
por: Elmore, Joshua, et al.
Publicado: (2015)

Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
por: González-Albarrán, Olga, et al.
Publicado: (2022)

Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Gan, Sushrima, et al.
Publicado: (2020)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

SGLT2i: beyond the glucose-lowering effect
por: Ni, Lihua, et al.
Publicado: (2020)

Mineral and Electrolyte Disorders With SGLT2i Therapy
por: Cianciolo, Giuseppe, et al.
Publicado: (2019)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

El derecho humano al medio ambiente sano : para el desarrollo y bienestar y al agua potable y saneamiento
por: Tejado Gallegos, Mariana
Publicado: (2014)

La contaminación del suelo por residuos peligrosos y su regulación en México /
por: Tejado Gallegos, Mariana
Publicado: (2014)

Perspective of SGLT2i in the Treatment of Abdominal Aortic Aneurysms
por: Jin, Zhongtiao, et al.
Publicado: (2023)

Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes
por: Garcia-Tirado, Jose, et al.
Publicado: (2022)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review
por: Delgado, Elías, et al.
Publicado: (2022)

Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study
por: Pérez-Carrillo, Lorena, et al.
Publicado: (2022)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
por: Cha, Seon-Ah, et al.
Publicado: (2017)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
por: Cianciolo, Giuseppe, et al.
Publicado: (2020)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

Response to cardiac resynchronization therapy and treatment with ARNi and iSGLT2
por: Fonderico, C, et al.
Publicado: (2023)

Timing of SGLT2i initiation after acute myocardial infarction
por: von Lewinski, Dirk, et al.
Publicado: (2023)

Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
por: Liao, Xiaoyu, et al.
Publicado: (2019)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021)

Taller de lectura y redacción I : claves para leer y escribir con sentido.
por: Márquez Hermosillo, Mónica
Publicado: (2014)

Identification of Polyphenols in Sea Fennel (Crithmum maritimum) and Seaside Arrowgrass (Triglochin maritima) Extracts with Antioxidant, ACE-I, DPP-IV and PEP-Inhibitory Capacity
por: Calvo, Marta María, et al.
Publicado: (2023)

Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19()
por: Carrasco-Sánchez, Francisco Javier, et al.
Publicado: (2022)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
por: Paolisso, Pasquale, et al.
Publicado: (2023)

Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
por: Rafey, Mohammed Faraz, et al.
Publicado: (2019)

Física I /
por: Cuéllar Carvajal, Juan Antonio
Publicado: (2013)

374 Effectiveness of an Educational Intensive Course on A/I Clinical and Diagnostic Procedures
por: Elizalde, Araceli, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0pfneu7rvkcmhf9a52a7qadpe6